2018 American Transplant Congress
Not All HLA Mismatches Are Equal: Determining the Relative De Novo DSA Induction Capacity of HLA Mismatches
We studied the immunogenicity, defined as the development of de novo DSA (dnDSA), of HLA-A, -B, -DR and -DQ MM (serological) in a cohort of…2018 American Transplant Congress
Can We Expect the “Unexpected”?
Northwestern University, Chicago.
A known, seemingly paradoxical, phenomenon of the HLA system is the high overall degree of homology among different HLA alleles, despite vast polymorphism in the…2018 American Transplant Congress
A Calculated Panel Reactive Antibody (CPRA) Calculator Supporting Both Allele-Level and Antigen-Level HLA Specificities
Introduction:The number of HLA alleles represented on Luminex assays has increased over time, allowing for improved characterization of anti-HLA antibody specificity. Calculated Panel Reactive Antibody…2018 American Transplant Congress
The Value of Serum Dilution on DSA Outcome Analysis in Renal Transplantation
Background: Recently, transplant centers have discussed the potential value of sera dilutions in assessment of donor specific anti-HLA antibodies (DSA). However, to date, no data…2018 American Transplant Congress
Epitope/Eplet Mismatch in Pediatric Renal Transplantation and Development of Donor Specific Antibody
Background: De-novo donor specific antibody (DSA) is one of the strongest independent predictors of graft loss with HLA mismatching being a major risk factor for…2018 American Transplant Congress
Increasing the Donor Pool for Highly Sensitized Patients with Allele Specific Antibodies: Optimizing the Virtual Crossmatch (vXM)
Background:Since implementation of the current Kidney Allocation System, highly sensitized patients with 98-100% cPRA (HSPs) are receiving ~10% of deceased donor kidneys compared to <2%…2018 American Transplant Congress
Biopsy Correlates of DSA in Antibody-Mediated Rejection: C4d vs Microvascular Inflammation Scores
Icahn School of Medicine at Mount Sinai, New York, NY.
Background: The diagnosis of antibody-mediated rejection (AMR) requires the presence of both the histologic features of AMR as well as donor-specific antibodies (DSA). Whether anti-HLA…2018 American Transplant Congress
Generation of Calculated Panel-Reactive Antibody Values Using a Reference Panel of Bone Marrow Donors
Introduction: Calculated panel-reactive antibody (CPRA) is the official metric of sensitization used by the United Network for Organ Sharing (UNOS) for kidney allocation. The reference…2018 American Transplant Congress
Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipients
BACKGROUND: Donor specific antibodies (DSA) have been implicated in the development of acute rejection (AR) and graft dysfunction in kidney transplant recipients (KTx). However, limited…2018 American Transplant Congress
Safety and Efficacy of Tocilizumab (anti-IL6R, TCZ) Therapy in the Treatment of Chronic Antibody Mediated Rejection (cABMR) in Pediatric Renal Transplant Recipients
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA.
Background: Development of de novo Donor specific antibodies (DSA) post renal transplantation puts pediatric patients(pts) at risk for ABMR and allograft failure (Kim JJ AJT…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 47
- Next Page »